Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments

Anticancer Research

Volumn 23, Issue 6 C, 2003, Pages 4831-4835

  Németh, Arpad ^a   Nadasi, E ^a   Gyongyi Z ^a   Olasz, L ^a   Nyarady, Z ^a   Ember, A ^a   Kvarda, A ^b   Bujdoso, L ^b   Arany, I ^c   Kiss, I ^a   Csejtey, I ^d   Ember, I ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Co Inst of State Health Services ^*  (Hungary)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d Markusovsky Teaching Hospital   (Hungary)

Author keywords

Chemotherapy; Gene expression; Head and neck cancer; Secondary tumours

Indexed keywords

BLEOMYCIN; CARCINOGEN; CISPLATIN; CYTOSTATIC AGENT; FLUOROURACIL; FOLINATE CALCIUM; METHOTREXATE; MYC PROTEIN; PROTEIN P53; RAS PROTEIN; RNA; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HEAD AND NECK CANCER; MOUSE; MUTAGENESIS; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE H RAS; PRIORITY JOURNAL; SECOND CANCER; TARGET ORGAN; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW; CISPLATIN; DISEASE MODELS, ANIMAL; FEMALE; HEAD AND NECK NEOPLASMS; METHOTREXATE; MICE; MICE, INBRED CBA; SPLEEN; VINCRISTINE;

EID: 10744220358     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hanann MA, al-Dakan AA, Hussain SS and Amer MH: Mutagenicity of cisplatin and carboplatin used alone and in combination with four anticancer dugs. Toxicology 55(1-2): 183-91, 1989.
2. Olasz L, Szabo I and Horvath A: A combined treatment for advanced oral cavity cancers. Cancer 62(7): 1267-74, 1988.
3. Olasz L, Toth B, Nemeth A and Tornoczky T: Results and failures of preoperative BVMM chemotherapy and irradiation in advanced oral cancers. Can Det Prev 22(suppl.1): s-118, 1998.
4. Olasz L, Nyarady Z, Nemeth A and Tornoczky T: A randomized study of cisplatin-combined chemotherapy protocol. Can Det Prev 24(suppl-1): s-248, 2000.
5. Cabelguenne A, Blons H, de Wazier I, Carnot F et al: P-53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clinic Oncol 18(7): 1465-1473, 2000.
6. Gebel T, Lantzsch H, Plessow K and Dunkelberg H: Genotoxicity of platinum and palladium compounds in human and bacterial cells. Mutat-Res 398(2-3): 183-190, 1997.
7. Blommaert FA, Michael C, Terheggen PM, Muggia FM et al: Drug induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunohistochemical method: interindividual variation and correlation with disease response. Cancer Res 53(23): 5669-5675, 1993.
8. Nemeth A, Gyongyi Z, Nadasi E, Ember A, Olasz L, Nyarady Z and Emberi I: Effect of Cisplatin treatment on early oncogene activation of oncogenes in vivo. In Vivo 16(5): 307-311, 2002.
9. Ember I, Kiss I and Nowrasteh G: Different H-2 haplotypes have strong influence on oncogene action. Anticancer Res 19: 1181-1186, 1999.
10. Sanderson BJ, Ferguson LR and Denny WA: Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat-Res 17(1-2): 59-70, 1996.
11. Chomczynski P and Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
12. Friedrich RE, Giese M, Riethdorf S and Loning T: P-53 mutation in smears of oral squamous cell carcinoma. Anticancer Res 20(6D): 4927-4930, 2000.
13. de Rosa I, Stabiano S, Lo Muzio L, Delfino M et al: Potentially maliganant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p-53, and c-myc, differentiation and prognosis. J Oral Pathol Med 28(6): 252-258, 1999.
14. Eversole LR and Sapp JP: C-Myc oncoprotein expression in oral precancerous and early cancerous lesions. Eur J Cancer Oral Oncol 29B(2): 131-135, 1993.
15. Leonard JH, Kearsley JH, Chenevix-Trench G and Hayward NK: Analysis of gene amplification in head and neck squamous cell carcinoma. Int J Cancer 19;48(4): 511-515, 1991.
16. Yanamoto S, Kawasaki G, Yoshitomi I and Mizuno A: p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94(5): 593-600, 2002.
17. Ember I, Raposa T, Varga Cs and Kiss I: Effect of different cyostatic protocols on oncogene expression in CBA/Ca mice. Anticancer Res 15: 1285-1288, 1995.
18. Ember I, Raposa T, Varga Cs, Herceg L and Kiss I: Carcinogenic effects of cytostatic protocols in CBA/Ca mice. In Vivo 9: 65-70, 1995.
19. Rose BR, Thompson CH, Tattersall MH, O'Brien CJ and Cossart YE: Squamous carcinoma of the head and neck: molecular mechanisms and potential biomarkers. Aust N Z J Surg 70(8): 601-606, 2000.
20. Ember I, Kiss I and Vermes E: Early effect of cyclophosphamide in oncogene activation in vivo. In Vivo 12: 201-208, 1998.